Stryker Corporation $SYK Shares Bought by Lyell Wealth Management LP

Lyell Wealth Management LP boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 5.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,610 shares of the medical technology company’s stock after acquiring an additional 2,077 shares during the quarter. Lyell Wealth Management LP’s holdings in Stryker were worth $14,273,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after buying an additional 133,892 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after buying an additional 69,851 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after buying an additional 741,542 shares in the last quarter. Norges Bank acquired a new stake in shares of Stryker in the fourth quarter valued at $1,822,272,000. Finally, Legal & General Group Plc grew its stake in shares of Stryker by 2.7% in the fourth quarter. Legal & General Group Plc now owns 2,366,107 shares of the medical technology company’s stock valued at $831,616,000 after buying an additional 62,817 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last 90 days. 4.60% of the stock is owned by insiders.

Stryker Trading Down 1.0%

SYK opened at $305.82 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The stock has a market capitalization of $117.24 billion, a price-to-earnings ratio of 35.40, a PEG ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business has a fifty day moving average price of $316.75 and a 200 day moving average price of $344.20.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s payout ratio is presently 40.74%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Needham & Company LLC dropped their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. BTIG Research dropped their price objective on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, Truist Financial reaffirmed a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.